NasdaqGS:ARWRBiotechs
Arrowhead’s Expanded 2026 Conference Circuit and Phase 3 RNAi Pipeline Might Change The Case For Investing In Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharmaceuticals recently highlighted its participation in multiple March 2026 healthcare conferences, including TD Cowen, Leerink, Jefferies, and Barclays, featuring fireside chats and investor meetings with materials available via its investor relations website.
Alongside this conference schedule, the company’s RNAi pipeline progress, including two Phase 3 candidates supported by major pharma collaborations, has drawn heightened analyst attention and optimism about its development...